Clinical trials: Nutritional and Metabolic Diseases
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation
Metabolic Syndrome, Hyperlipidemia
The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome
The purpose of this study is to determine the effectiveness of ProAlgaZyme in increasing levels of HDL 'good' cholesterol and decreasing total cholesterol and C-reactive protein in patients with Metabolic Syndrome.
- Trial name
- NCT00518960
- Testing
- ProAlgaZyme
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Health Enhancement Products, Inc.
Hypertriglyceridemia, Cardiovascular Disease
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent…
- Trial name
- ESPRIT (NCT01408303)
- Testing
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Where
- 89 sites in United States
- Volunteers
- 646 people
- Sponsor
- AstraZeneca
Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn
Market Research of a Slow Release Protein Substitute for the Dietary Management of PKU
XPhePiccosMR is a prospective, single-arm, open label, observational study that aims to evaluate the acceptability and tolerability of XPhe Piccos, a slow-release, phenylalanine-free protein substitute in the form of tiny…
- Conditions
- Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn, Brain Disorder, Metabolic, Brain Diseases
- Trial name
- XPhePiccosMR (NCT07802366)
- Testing
- Slow release, phenylalanine-free protein substitute tablets
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- metaX Institut fuer Diatetik GmbH
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04537637)
- Testing
- Oral Semaglutide
- Where
- 2 sites in Denmark
- Volunteers
- 99 people
- Sponsor
- Novo Nordisk A/S
Amyotrophic Lateral Sclerosis (ALS)
A First in Human Study of ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of…
- Trial name
- NCT06769620
- Testing
- ORT247
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Orthogonal Neuroscience Inc.
Chronic Kidney Disease, Dialysis
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00772382
- Testing
- MCI-196
- Where
- 21 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Tanabe Pharma Corporation
Osteoporosis
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
- Trial name
- NCT01478724
- Testing
- Milk proteins fraction
- Where
- France
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Soredab
Obesity & Overweight
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants…
- Trial name
- SLIM-1 (NCT07430059)
- Testing
- Semaglutide Implant (NPM-139), Semaglutide (Wegovy) weekly injection
- Volunteers
- 20 people
- Sponsor
- Vivani Medical, Inc
Osteoporosis
Comparison of Osteoporosis Disease Management Strategies (0000-039)
The purpose of this study is to assess the impact of disease management interventions on bone mineral density screening rates and osteoporosis treatment rates in women age 50-64 years at high risk for osteoporosis.
- Trial name
- NCT00145080
- Testing
- Disease Management Assessment
- Volunteers
- 4,685 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.
- Trial name
- NCT00234988
- Testing
- sibutramine hydochloride monohydrate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Abbott
Cystinosis
Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)
Cystadrops® is currently indicated in adults and children from 2 years of age diagnosed with cystinosis with corneal crystal accumulation observed.
- Trial name
- SCOB2 (NCT04125927)
- Testing
- Mercaptamine
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 5 people
- Sponsor
- RECORDATI GROUP
Type 2 Diabetes Mellitus
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes.
- Trial name
- NCT00972322
- Testing
- MK-8245
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatolenticular Degeneration; Wilson
Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease
The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from Wilson's Disease. The main questions it aims to answer are: Does the device work as expected by removing the excess of…
- Trial name
- MEXWILS (NCT05917327)
- Testing
- Low-volume continuous veno-venous haemodialysis
- Where
- 4 sites in France, Spain
- Volunteers
- 1 people
- Sponsor
- Mexbrain
Osteoporosis, Postmenopausal
Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual…
- Trial name
- NCT01416194
- Testing
- Bazedoxifene, Bisphosphonate, Raloxifene
- Volunteers
- 10,497 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months.
- Trial name
- CAN-TREAT (NCT03674866)
- Testing
- Insulin degludec
- Where
- 32 sites in Canada
- Volunteers
- 662 people
- Sponsor
- Novo Nordisk A/S
Obesity
Clinical Feasibility Study of the BariTon™ System in Obese Patients
Safety evaluation of BariaTek Medical gastric restriction and biliodigestive diversion device.
- Trial name
- NCT06317129
- Testing
- Endoscopic gastric restriction and biliodigestive diversion
- Where
- Uzbekistan
- Volunteers
- 10 people
- Sponsor
- BariaTek Medical
Overweight and Obesity
A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.
A Phase 1, double-blind, randomized study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of single dose and multiple doses of CG-0416 in healthy participants. HongKong Curegene Innovation Co.
- Trial name
- NCT07724431
- Testing
- CG-0416
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HongKong Curegene Innovation Co., Limited
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.